Scottish researchers examined data for 1.75 million people registered with 393 general practices. They studied a total of 56,658 subjects.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
The researchers found that in men, heart failure had worse mortality outcomes than prostate cancer and bladder cancer. The five-year survival rate among men is:
• 55.8 percent for heart failure
• 57.3 percent for bladder cancer
• 68.3 percent for prostrate cancer
However, heart failure survival rates were higher for lung cancer and colorectal cancer.
Among women, heart failure had worse mortality outcomes than breast cancer. The five-year survival rate for heart failure and breast cancer were 49.5 percent and 77.7 percent respectively. However, heart failure survival rates were higher compared to survival rates for colorectal cancer, lung cancer and ovarian cancer.
“Despite advances in management, [heart failure] remains as ‘malignant’ as some of the common cancers in both men and women,” study authors conclude.
More articles on healthcare quality:
Leapfrog: Hospitals aren’t using medication safety technology effectively
Follow-up colonoscopies can significantly reduce colorectal cancer in certain high-risk patients, study finds
Minnesota measles outbreak jumps to 29 cases
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
